I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Quick facts

Marketed products

• clopidogrel/abciximab · Cardiovascular
  This combination uses clopidogrel to inhibit platelet aggregation via P2Y12 receptor blockade and abciximab to block the glycoprotein IIb/IIIa receptor, providing dual antiplatelet effects.
• Didrogyl · Other
• prasugrel/bivalirudin · Cardiovascular
  Prasugrel and bivalirudin are combined to provide dual antiplatelet and anticoagulant activity for acute coronary syndrome management.

Phase 2 pipeline

• ASC secretome
• Harvesting of muscular biopsies
• Isolation of multipotent cells

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio portfolio CI brief
• I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio pipeline updates RSS

Frequently asked questions about I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio

Related

• clopidogrel/abciximab · Cardiovascular
• Didrogyl · Other
• prasugrel/bivalirudin · Cardiovascular
• Sector hub: All tracked pharma companies